

The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter

Mark D Sternlicht^{*1}, Mina J Bissell² and Zena Werb¹

¹Department of Anatomy, University of California, 513 Parnassus Avenue, HSW-1301, San Francisco, California, CA 94143-0452, USA; ²Life Sciences Division, Lawrence Berkeley National Laboratory, California, CA 94720, USA

Extracellular matrix-degrading matrix metalloproteinases (MMPs) are invariably upregulated in epithelial cancers and are key agonists in angiogenesis, invasion and metastasis. Yet most MMPs are secreted not by the cancer cells themselves, but by stromal cells within and around the tumor mass. Because the stromal environment can influence tumor formation, and because MMPs can alter this environment, MMPs may also contribute to the initial stages of cancer development. Several recent studies in MMP-overexpressing and MMP-deficient mice support this possibility, but have required carcinogens or pre-existing oncogenic mutations to initiate tumorigenesis. Here we review the spontaneous development of premalignant and malignant lesions in the mammary glands of transgenic mice that express an autoactivating form of MMP-3/stromelysin-1 under the control of the whey acidic protein gene promoter. These changes were absent in nontransgenic littermates and were quenched by co-expression of a human tissue inhibitor of metalloproteinases-1 (TIMP-1) transgene. Thus by altering the cellular microenvironment, stromelysin-1 can act as a natural tumor promoter and enhance cancer susceptibility. *Oncogene* (2000) 19, 1102–1113.

Keywords: matrix metalloproteinases; stromelysin; TIMP; mammary carcinogenesis; epithelial-to-mesenchymal conversion

Introduction

Matrix metalloproteinases (MMPs) are consistently upregulated in epithelial cancers, and considerable evidence indicates that they play an essential role in tumor angiogenesis, invasion and metastasis by virtue of their combined ability to degrade virtually all elements of the extracellular matrix (ECM) (Coussens and Werb, 1996). Indeed, without the help of ECM-degrading enzymes, cancer cells would probably be unable to cross the matrix barriers that otherwise contain their spread. This straightforward and conceptually appealing supposition forms the basis for current clinical trials of MMP inhibitors as anti-cancer agents. However, in addition to promoting cellular invasion by simply clearing away the surrounding matrix, MMPs can alter cellular signals (Lukashev and Werb, 1998; Werb, 1997) and may therefore influence initial tumor development. If so, then the inhibition of select MMPs during even the earliest stages of cancer progression may offer clinical benefit.

The MMP stromelysin-1 (MMP-3, Str1) exhibits a number of activities that would make it a particularly good tumor promoter. Like several other MMPs, *Str1* was first cloned and later recloned as a cancer-specific gene (Matrisian *et al.*, 1985; Muller *et al.*, 1988; Ostrowski *et al.*, 1988). In addition to degrading numerous ECM components, Str1 can activate gelatinase B and the collagenases, and can activate several serpin-type serine proteinase inhibitors (Sternlicht and Werb, 1999, for review). Moreover, it can release a number of cell surface molecules, including E-cadherin (Lochter *et al.*, 1997a), a known contributor to cancer development (Christofori and Semb, 1999; Tlsty, 1998).

Str1 is expressed by stromal cells during normal mammary gland development, and is strongly up-regulated during post-lactational mammary involution when considerable ECM remodeling and alveolar apoptosis occur (Lund *et al.*, 1996; Thomasset *et al.*, 1998; Witty *et al.*, 1995). Interestingly, E-cadherin cleavage also occurs during involution and may induce apoptosis (Vallorosi *et al.*, 1999). Alternatively, ECM degradation may induce the apoptosis that occurs during involution. Either way, Str1 could act as an apoptotic stimulus. Indeed, Str1 does induce apoptosis in differentiated mammary alveolar epithelial cells in culture and *in vivo*, however it also promotes the proliferation and branching of ductal epithelium (Alexander *et al.*, 1996; Boudreau *et al.*, 1995; Sympton *et al.*, 1994; Thomasset *et al.*, 1998; Witty *et al.*, 1995). These seemingly contradictory effects can be reconciled by noting that ductal epithelial cells normally divide during branching morphogenesis and persist throughout involution, whereas alveolar epithelial cells do not. Thus the differentiation status of the target cell may determine its response to Str1. These effects were first observed in transgenic mice with an autoactivating rat *Str1* transgene – (the autoactivating rat Str1 cDNA contained a Val⁹²-to-Gly⁹² transition within its propeptide domain, thus destabilizing the ‘cysteine switch’ that otherwise maintains enzyme latency (Sanchez-Lopez *et al.*, 1988)) – targeted to mammary epithelium by the whey acidic protein (WAP) gene promoter (Sympton *et al.*, 1994) and mouse mammary tumor virus (MMTV) enhancer/promoter (Witty *et al.*, 1995). In these mice, *Str1* transgene expression resulted in increased ductal branching and precocious lobulo-alveolar development during puberty, basement membrane disruption and unscheduled involution during pregnancy, and alveolar collapse and low milk-protein production during lactation. Expression of the *Str1* transgene during pregnancy and lactation also led to enhanced expression of endogenous Str1 by mammary fibroblasts, collagen accumulation (fibrosis), neovascularization,

*Correspondence: MD Sternlicht

and tenascin-C expression (Thomasset *et al.*, 1998). These changes are not only hallmarks of the reactive stroma seen during involution, but are also seen during cancer progression (Borsi *et al.*, 1992; Rønnov-Jessen *et al.*, 1996) and may even predispose toward neoplastic epithelial transformation (Jacobs *et al.*, 1999; Jacoby *et al.*, 1997; Kinzler and Vogelstein, 1998; Willenbacher *et al.*, 1999). Furthermore, the proliferative effects of Str1 could support neoplastic transformation and its apoptotic effects could help select apoptosis-resistant clones. Thus Str1 triggers a number of changes (increased cell proliferation, apoptosis, angiogenesis, and an altered stromal environment) that could potentially promote mammary carcinogenesis.

The above effects, which might be viewed as a prelude to cancer, were observed in transgenic animals under 4 months of age. To further address the potential tumor promoting activity of Str1, mammary gland changes were monitored in WAP-Str1 transgenic mice from 6–24 months of age. We observed the development of spontaneous premalignant lesions and mammary cancers in these mice and the virtual absence of such changes in their nontransgenic littermates and in related bitransgenic mice that co-express a human tissue inhibitor of metalloproteinases (TIMP-1) transgene under the control of the same promoter (Sternlicht *et al.*, 1999). These Str1-induced changes which occur in the absence of exogenous mutagens or endogenous oncogene or suppressor gene defects, offer strong evidence that Str1 can indeed act as a natural tumor promoter.

Str1 promotes mammary carcinogenesis

To evaluate the effects of prolonged Str1 expression in the mammary gland, WAP-Str1 transgenic mice from five independent CD-1 founder lines and nontransgenic controls were maintained under similar conditions for up to 2 years (Sternlicht *et al.*, 1999). Only 12% of all WAP-Str1 transgenic mice had histologically normal mammary glands. Instead, about three-quarters had moderate-to-severe fibrosis, about half had epithelial hyperplasias, 20% had atypical hyperplasias (dysplasias) or ductal carcinoma *in situ*, and 7% developed malignant mammary carcinomas (Table 1). Lymphocytic infiltrates accompanied these lesions in about half of all transgenic mice. By comparison, 87% of the nontransgenic mice had entirely normal mammary glands, and the remaining 13% had only mild fibrosis, hyperplasia or lymphocytic infiltration, and none of the more severe lesions seen in the animals expressing the Str1 transgene. These genotype-specific differences were highly significant ($P < 0.002$ for carcinoma development and $P < 0.0001$ for all other pathologies).

Approximately one-third of the mice from each group were carried through pregnancy and lactation. Parity had no effect on the already low incidence of mammary changes seen in the nontransgenic mice, and slightly increased the incidence of each type of lesion in the transgenic mice (Table 1). The hyperplastic and fibrotic lesions also tended to be somewhat more severe in the parous subset of transgenic mice. The absence of more profound differences between parous and nulliparous mice, despite the use of a pregnancy-responsive promoter, probably reflects the low-level activity of the

Table 1 Incidence of mammary gland pathologies in WAP-Str1 transgenic mice

	Wap-Str1 transgenic mice			Nontransgenic	
	Virgin	Parous	All mice	All mice	P*
N	105	58	163	119	
Median age (mos.)	18	17	18	18	
No pathology	17 (16%)	3 (5.2%)	20 (12%)	104 (87%)	<0.0001
Fibrosis	74 (70%)	51 (88%)	125 (77%)	8 (6.7%)	<0.0001
Lymphoid infiltrates	51 (49%)	36 (62%)	87 (53%)	10 (9.3%)	<0.0001
Hyperplasia	65 (62%)	40 (69%)	105 (64%)	6 (5%)	<0.0001
Dysplasia	18 (17%)	15 (26%)	33 (20%)	0 (0%)	<0.0001
Carcinoma	6 (5.7%)	6 (10%)	12 (7.4%)	0 (0%)	0.0016

*Two-tailed Fisher's exact test versus all transgene-expressing mice

promoter during each estrus cycle which, in turn, would limit the increase in overall lifetime exposure to Str1 that would be gained through parity.

Abnormalities of varying severity were usually seen in all of the mammary glands examined in an individual transgenic mouse, and multiple abnormalities were often seen within individual mammary glands (Figures 1 and 2). Fibrotic changes included periductal, intralobular and diffuse accumulations of interstitial collagen and fibroblasts (Figure 1). In addition, fibrosis was often seen adjacent to or admixed with multi-loculated adipocytes (Figure 2), a feature that may reflect the dedifferentiation of adipocytes towards a matrix-producing fibroblastic phenotype. Hyperplastic lesions included discrete hyperplastic alveolar nodules (HANs), multifocal and diffuse alveolar hyperplasias, adenomatous hyperplasias, and papillary ductal hyperplasias (Figures 1–4). Alveolar-type hyperplasias were most common. These were packed with otherwise normal alveoli containing a single layer of luminal epithelial cells surrounded by a single layer of myoepithelial cells (Figure 3). Several alveolar hyperplasias displayed evidence of secretory activity with apical lipid vacuolization of the luminal cells, luminal eosinophilic concretions resembling residual (inspissated) milk, and enlarged (ectatic) ducts containing proteinaceous material and lipid droplets (Figures 2 and 3). Papillary lesions, on the other hand, contained multilayered mounds of cells within distended ducts (Figure 4). In addition, myoepithelial cells were not only present in their normal position between the luminal epithelial cells and basement membrane, but were also abnormally located within the ducts as a result of the inward growth and folding of the papillary projections (Figure 4c–e). Dysplastic lesions also showed multiple cell layering, but with attenuated myoepithelial cell staining in some areas.

Twelve mammary carcinomas developed in the transgenic mice with only two arising before 1 year of age and an average tumor latency of 18.7 months. Hyperplastic or dysplastic lesions and a fibrotic (scirrhous or desmoplastic) stroma were consistently found adjacent to the malignant tumors (Figures 1 and 5). For the most part, however, the tumors were histologically and cytologically diverse. One large adenocarcinoma with adjacent papillary lesions contained unusual, internally located myoepithelial cell islands (Figure 5). Otherwise, myoepithelial cells were uniformly absent in the tumors. The mesenchymal




Figure 1 Masson's trichrome-stained mammary gland sections from (a) nontransgenic and (b–d) WAP-*Str1* transgenic mice. The normal nontransgenic gland contains relatively few resting ducts surrounded by scant periductal collagen and embedded in an adipose stroma, whereas each transgenic gland exhibits extensive accumulation of blue-stained collagen (fibrosis) and few residual adipocytes. (b) This gland from a 7-month-old transgenic mouse contains numerous collapsed alveolar structures and extensive periglandular fibrosis. (c) A large dilated duct containing proteinaceous secretory material and hyperplastic alveolar epithelial cells with secretory vacuolization are apparent in this gland even though this 16-month-old transgenic mouse had never been pregnant. (d) This section from a 10-month-old transgenic mouse contains secretory hyperplastic epithelial cells and fibrosis adjacent to a secretory adenocarcinoma. Scale bar, 150 μ m

intermediate filament marker vimentin was absent in the nine tumors that were well- or moderately well-differentiated, except, of course, in their surrounding and intervening stroma (Figure 5h). The three remaining undifferentiated tumors, however, each exhibited vimentin immunoreactivity in addition to epithelial cytokeratin staining. One of these tumors gave rise to multiple lung and kidney metastases and stained positive for both vimentin and cytokeratins (Figure 6a–c). It also gave rise to a tumor cell line (TCL-1) (Lochter *et al.*, 1997b) that continued to express both intermediate filament markers in culture (Figure 6d–f) and formed highly metastatic spindle-cell tumors that remained cytokeratin- and vimentin-positive in nude mice (Figure 6g–i). The other undifferentiated tumors were carcinosarcomas (carcinomas with sarcomatous metaplasia) that contained distinct epithelial-like (carcinomatous) and mesenchymal-like (sarcomatous) cell populations (Figure 6j–l). The fibroblast-like sarcomatous cells had malignant cytologic features, composed the majority of some parts of the tumor, and contained similar genomic changes to those seen in the carcinomatous cells (Sternlicht *et al.*, 1999), thus indicating that they did not merely represent a stromal response to the

malignant epithelial-like cells. Furthermore, both cell populations persisted after serial transplantation to immunocompromised mice. Thus, even though carcinosarcomas are extremely rare in humans and in mice, one-sixth of the tumors in WAP-*Str1* mice were of this type, and one-quarter of all tumors exhibited some degree of epithelial-to-mesenchymal phenotypic conversion. This incidence is intriguing in light of recent data indicating that phenotypically normal mammary epithelial cells undergo epithelial-to-mesenchymal conversion in response to *Str1* in culture and *in vivo* (Lochter *et al.*, 1997a; Sternlicht *et al.*, 1999). This phenomenon has been associated with more aggressive malignant behavior (Birchmeier *et al.*, 1996; Gilles and Thompson, 1996), and careful examination reveals that a large percentage of human tumors, and perhaps all poorly differentiated tumors, exhibit some degree of epithelial-to-mesenchymal conversion (Oft *et al.*, 1998). Because most MMPs are stromal (mesenchymal) cell products, cancer cells begin to secrete their own MMPs only when they undergo such an epithelial-to-mesenchymal phenotypic transition (Ahmad *et al.*, 1998; Martorana *et al.*, 1998; Wright *et al.*, 1994). Thus, *Str1* may represent both a cause and a consequence of epithelial-to-mesenchymal conversion.




Figure 2 Carmine-stained wholemount (a,b) and H&E-stained paraffin section (c–e) of an abdominal (#4) mammary gland with diffuse hyperplasia (hp), fibrosis (fi) and lymphocytic infiltration (ly) from a 15-month-old parous WAP-*Str1* mouse sacrificed 4 months after its pups were removed. The hyperplastic branches indicated by the arrow in (a) are outlined in (c) and are shown at higher magnification in (b and d). These sparse and disproportionately short secondary branches terminate in relatively well-developed lobuloalveolar structures and are surrounded by multilocular adipocytes (asterisk). The boxed area to the left of the central lymph node (LN) in c is enlarged in e and shows three hyperplastic areas, each with a distinct histologic appearance. Dilated (ectatic) primary ducts (du) containing considerable amounts of residual secretory material are also evident throughout the gland. Scale bars, 5 mm (a,c), 500 μ m (b,d,e)

TIMP-1 inhibits mammary neoplasia in Str1 transgenic mice

If the proteolytic activity of Str1 is responsible for the development of premalignant and malignant neoplasms in *Str1* transgenic mice, then these changes should be quenched by overexpression of its natural inhibitor, TIMP-1. We previously showed that mating the *Str1* transgenic mice with mice that overexpress a human *TIMP1* transgene driven by the constitutive β -actin

gene promoter abolishes the ECM degradation and unscheduled apoptosis otherwise seen in young pregnant *Str1* transgenic mice (Alexander *et al.*, 1996). To test the ability of TIMP-1 to counter the long-term effects of Str1 in the mammary gland, WAP-*Str1* transgenic mice were crossed with mice that expressed the human *TIMP1* transgene under the control of the same WAP promoter. Using mammary hyperplasia as a surrogate end-point, 73% of 10–16-month-old offspring carrying the *Str1* transgene alone, but only




Figure 3 Histologic appearance of hyperplastic alveolar nodules (HANs) from 23- (a), 16- (b), 24- (c) and 12-month-old (d–f) virgin WAP-*Str1* transgenic mice as seen by wholemount (a–c), H&E (d), anti-cytokeratin-8 immunoperoxidase (e) and anti-smooth muscle actin immunoperoxidase (f) staining. The multiple alveolar structures are composed of an internal layer of cytokeratin-8-positive luminal epithelial cells with lipid vacuolization (e) surrounded by a single smooth muscle actin-positive myoepithelial cell layer (f). Adjacent normal areas (nl) contain mostly adipocytes and sparse ducts with the same bilayered luminal and myoepithelial cell staining, but without secretory vacuoles. LN, lymph node. Scale bars, 2 mm (a–c), 100 μ m (d–f)




Figure 4 Histologic appearance of a florid papillary hyperplasia (intraductal papillomatosis) in the mammary gland of a 2-year-old virgin WAP-*Str1* transgenic mouse as seen by wholemount (a), H&E (b,c), anti-smooth muscle actin (d) and anti-cytokeratin-8 (e) staining. The area outlined in (b) is shown at higher magnification in (c–e). The small, basophilic cells within the papillary projections (me) are smooth muscle actin-positive (d) and cytokeratin-8-negative (e), indicating the abnormal, internal presence of myoepithelial cells. Although small focal collections of lymphocytes were present (not shown), fibrosis was not observed and the far ends of the gland were essentially normal. Scale bars, 2 mm (a,b), 200 μ m (c–e)

19% of age-matched bitransgenic mice carrying both the *Str1* and *TIMP1* transgenes developed hyperplasia ($P < 0.02$, two-tailed Fisher's exact test). The double-transgenic mice also had a significantly lower incidence of hyperplasia than the whole cohort of WAP-*Str1* mice included in Table 1 ($P < 0.0006$). The few hyperplasias that did develop in the bitransgenic mice

were considerably milder than those observed in the single-transgenic littermates with WAP-*Str1* alone. Parity did not significantly alter the incidence or severity of mammary hyperplasia in the single or double-transgenic mice. Mammary hyperplasias were also uniformly absent in those littermates with only the *TIMP1* transgene and in nontransgenic littermates.




Figure 5 Histologic appearance of moderately well-differentiated mammary adenocarcinomas from 15- (**a,b**), 19- (**c–e**) and 23-month-old (**f–h**) WAP-*Str1* transgenic mice as seen after wholemount (**a**), H&E (**b,c,f**), anti-cytokeratin-8 (**d,g**), anti-smooth muscle actin (**e**) and anti-vimentin (**h**) staining. (**a,b**) The tumor at right contains cystic spaces and necrotic debris, and sits adjacent to a diffuse lactational-like hyperplasia (asterisk) and a lymph node (LN) that is surrounded by muscle. The strip of connective tissue and skeletal muscle (arrow) is indicated for orientation. (**c–e**) This complex tumor (at right in each panel) contains numerous cystic spaces and tumor cell nests composed of mixed small and large cell populations. The small cells are smooth muscle actin-positive (**e**) and have small nuclei with a dense chromatin structure. The larger cells are cytokeratin-8 positive (**d**), have larger nuclei with a more open chromatin structure, and exhibit distinct intercellular bridges. The tumor is surrounded by a fibrotic stroma, atypical papillary lesions (**c**) and areas of secretory hyperplasia (asterisk). (**f–h**) These serial sections show a papillary adenocarcinoma with large cytokeratin-positive tumor cells, numerous mitotic figures, and an abundant vimentin-positive stroma (st). Scale bars, 2 mm (**a,b**), 300 μ m (**c**), 200 μ m (**d,e**), 50 μ m (**f–h**)

Thus it is the enzymatic activity of Str1 that is required to promote mammary neoplasia.

Other MMPs can promote carcinogenesis

Several recent observations support a role for MMPs early in cancer development. For example, mice that express a human collagenase-1 (MMP-1) transgene in squamous epithelium develop hyperproliferative skin lesions, and although they fail to form tumors spontaneously, they are more sensitive to chemical carcinogens than their non-transgenic littermates (D'Armiento *et al.*, 1995). Conversely, mice that lack stromelysin-3 (MMP-11) form fewer and smaller DMBA-induced tumors than wild-type mice (Masson *et al.*, 1998). Moreover, wild-type fibroblasts foster the

tumorigenicity of human MCF-7 breast cancer cells in nude mice, whereas fibroblasts without MMP-11 do not (Masson *et al.*, 1998). Because ECM-associated growth factors are also required for MCF-7 tumorigenicity, the authors propose that MMP-11 may promote tumor formation by causing the release or activation of sequestered growth factors. The lack of matrilysin (MMP-7) in mice carrying the *Apc^{min}* mutation hinders the development of benign intestinal adenomas (Wilson *et al.*, 1997), and its overexpression in mammary tissue accelerates mammary tumor formation in mice carrying an MMTV promoter-driven *ErbB-2/neu* transgene (Rudolph-Owen *et al.*, 1998). In addition, MMTV-MMP-7 transgenic mice develop premalignant hyperplastic alveolar nodules (HANs) even in the absence of MMTV-*neu*, whereas their non-




Figure 6 Histologic appearance of poorly-differentiated mammary tumors and a tumor-derived cell line from WAP-*Str1* transgenic mice. (a) This H&E-stained area of primary mammary cancer from a 16-month-old virgin mouse contains spindle-shaped cells (left) and polygonal, epithelial-like tumor cells at lower right. (b,c) These two lung metastases from the tumor in (a) also contain spindled and polygonal cancer cells and stain positive for both cytokeratins (c) and vimentin (not shown). (d–f) The tumor cell line (TCL-1) established from the tumor in (a) exhibits a spindle-cell morphology and cytokeratin (d) and vimentin (e) immunoreactivity by dual immunocytochemistry and DAPI counterstaining (f). (g–i) TCL-1-derived tumors in immunocompromised mice show a pure spindle-cell morphology and numerous mitotic figures by H&E (g) and continue to stain positive for both cytokeratins (h) and vimentin (i). (j–l) Serial sections of this carcinosarcoma from a 17-month-old virgin transgenic mouse reveal a mixed cellular morphology by H&E (j) with polygonal carcinomatous cells that are cytokeratin-positive (k) and spindle-shaped sarcomatous cells that are vimentin-positive (l). Scale bars 100 μm (a,c), 200 μm (b), 50 μm (d–i), 75 μm (j–l)

transgenic littermates do not (Rudolph-Owen *et al.*, 1998). The lack of either *Str1* or gelatinase B (MMP-9) inhibits the development of human papilloma virus-16-induced squamous cell carcinomas in transgenic mice (LM Coussens, D Hanahan and Z Werb, unpublished observations). Furthermore, those tumors that develop despite the lack of MMP-9 tend to be more aggressive than usual, suggesting that MMP-9-deficiency provides pressure for the selection of less differentiated cancers that are better able to overcome the absence of MMP-9 (unpublished observations). Other MMPs that are highly expressed in malignant disease, such as MMP-

19 (Grant *et al.*, 1999), may also influence cancer progression, but remain essentially unexplored. (Because the GenBank sequences submitted as human MMP-18 and 19 are identical but substantially different from the *Xenopus* MMP-18 sequence, they are designated as MMP-19).

Although the above studies support a role for MMPs in early tumor progression and indicate that MMPs may increase neoplastic risk, they still required pre-existing oncogene or suppressor gene mutations or the administration of chemical carcinogens to achieve tumorigenesis. Here, however, we have described the

spontaneous development of Str1 transgene-induced lesions in the absence of such mutations or mutagens. These changes, which failed to occur in non-transgenic controls, were also quenched by coexpression of a TIMP-1 transgene. Thus their spontaneous development lends even greater support to the likelihood that MMPs profoundly influence early tumor initiation and development.

In addition to MMPs, closely related metalloproteinases, such as the membrane-anchored ADAM (a disintegrin and metalloproteinase domain) and the secreted ADAMTS (thrombospondin domain-containing) proteins, are likely to influence cancer progression (Vazquez *et al.*, 1999; Werb and Yan, 1998). For example, tumor necrosis factor- α converting enzyme (TACE, ADAM-17) can clearly influence cancer progression. Recent data also suggest that an unidentified metalloproteinase causes Fas ligand to be shed from cells, thus enabling them to avoid Fas-mediated apoptosis (Mitsiades *et al.*, 1999). In addition, a unique metalloproteinase that is inhibited by TIMP-1 but not TIMP-2 causes cleavage and shedding of the extracellular domain of the *ErbB2/neu* growth factor receptor (Codony-Servat *et al.*, 1999). Such shedding, which is often observed in breast cancer patients, may have oncogenic consequences and may limit the efficacy of anti-*ErbB2*-directed therapy. Other ADAM and ADAMTS domains may also influence cancer progression. For example, the cysteine-rich domain of meltrin- α (ADAM-12) can support tumor cell adhesion (Iba *et al.*, 1999). Some members of these multi-gene families may even play conflicting roles in cancer due to the presence of domains with distinct biologic activities. For example, the potent anti-angiogenic activity of some ADAMTS (metalloproteinase) family members (Vazquez *et al.*, 1999) may exert tumor suppressive effects, while other domains may promote tumor progression.

TIMPs may promote and suppress carcinogenesis by distinct mechanisms

If, in fact, MMPs promote carcinogenesis, then their endogenous inhibitors, the TIMPs, should defy cancer development. However, whereas some studies do suggest that TIMPs suppress tumor development, others do not. In support of a tumor suppressive role, antisense depletion of TIMP-1 renders murine 3T3 cells tumorigenic *in vivo* (Khokha *et al.*, 1989). In addition, the transformation-promoting activity of the prototypic tumor promoter 12-*O*-tetradecanoylphorbol-13-acetate (TPA) is inhibited by TIMPs 1 and 2 in culture (Shoji *et al.*, 1997). Thus, the well-known ability of TPA to promote tumors *in vivo* may be partly due to its ability to upregulate MMP gene expression (Gack *et al.*, 1994; Reichardt *et al.*, 1998). On the other hand, TPA also upregulates TIMP-1 gene expression (Logan *et al.*, 1996; Lu *et al.*, 1991). In double transgenic mice, TIMP-1 overexpression inhibits simian virus 40 T antigen-induced hepatocellular carcinogenesis by inhibiting hepatocyte proliferation and angiogenesis (Martin *et al.*, 1996, 1999). TIMP-1 overexpression also inhibits the tumorigenicity of melanoma and lymphoma cells (Khokha, 1994; Krüger *et al.*, 1997). However, in an experimental metastasis assay, certain tumor cell lines were better able to grow in the

presence of tumor-associated TIMP-1, suggesting that it may protect ECM or cell surface molecules that are critical for cell viability (Soloway *et al.*, 1996). TIMP-1 overexpression also appears to promote intestinal adenoma formation in *Min* mice, yet a synthetic MMP inhibitor decreases tumor multiplicity in this same model (Heppner Goss *et al.*, 1998). This discrepancy may reflect the growth-promoting activity of TIMP-1, a function that point-mutation studies indicate is independent of its MMP-inhibitory activity (Chesler *et al.*, 1995). Indeed, TIMP-1 was initially cloned as 'EPA' by virtue of its erythroid-potentiating activity (Docherty *et al.*, 1985) and has been shown to act as a mitogen for other cell types (Bertaux *et al.*, 1991). Thus it is not entirely counterintuitive that TIMP-1 is often upregulated in human cancers (Kossakowska *et al.*, 1996; Lindsay *et al.*, 1997; Yoshiji *et al.*, 1996) and that such upregulation is predictive for metastatic progression and a poor prognosis (Jung *et al.*, 1997; McCarthy *et al.*, 1999; Mimori *et al.*, 1997; Ree *et al.*, 1997; Zeng *et al.*, 1995). Although TIMP-1 upregulation may simply be a consequence of the increased matrix remodeling that occurs during invasion, and would certainly hinder the pro-oncogenic and pro-invasive effects of MMPs, emerging evidence indicates that TIMP upregulation could also benefit tumors. In addition to its growth-stimulatory activity, recent studies indicate that TIMP-1 can upregulate vascular endothelial growth factor expression (Yoshiji *et al.*, 1998), that it can exert anti-apoptotic activity (Guedez *et al.*, 1998a,b), and that it may even be internalized by cells and translocated to the nucleus (Ritter *et al.*, 1999).

Like TIMP-1, TIMP-2 promotes cell growth in culture (Hayakawa *et al.*, 1994; Nemeth *et al.*, 1996; Stetler-Stevenson *et al.*, 1992) and appears to inhibit tumor growth *in vivo* (Imren *et al.*, 1996). Although some studies indicate that TIMP-2 expression tends to be similar in tumors and matched normal tissues (Stetler-Stevenson *et al.*, 1990), others have found a significant correlation between TIMP-2 expression and the development of distant metastases (Ree *et al.*, 1997). Unlike TIMP-1, TIMP-2 expression is down-regulated by TGF- β 1 and is unaffected by serum and phorbol esters, each of which increase TIMP-1 expression (Leco *et al.*, 1992).

The role of TIMP-3 in cancer is also unclear. Some studies indicate that TIMP-3 is upregulated in human tumors (Uriá *et al.*, 1994) and may provide an early marker for malignant disease (SP Hawkes, personal communication). Others, however, indicate that the TIMP-3 gene promoter is epigenetically downregulated during cancer development (Bachman *et al.*, 1999). Like TIMP-1, TIMP-3 is induced during cell transformation in culture (Lu *et al.*, 1991; Staskus *et al.*, 1991). TIMP-3 is also transiently induced by hepatocyte growth factor (HGF) (Castagnino *et al.*, 1998), which, in turn, has been implicated in mesenchymal-to-epithelial cellular conversion (Tsarfaty *et al.*, 1994). Interestingly, ectopic overexpression of TIMP-3 can also induce mesenchymal-to-epithelial conversion and loss of malignant characteristics in cultured sarcoma cells, and its antisense depletion has the opposite effect, suggesting that it may be a mediator of HGF activity (Castagnino *et al.*, 1998). In addition, TIMP-3 is the only known endogenous inhibitor of TACE (Amour *et*

al., 1998). Thus, it may also influence cancer development by inhibiting TACE and other relevant ADAM and ADAMTS family members. Alternatively, some ADAM and ADAMTS proteins may be inhibited by other TIMPs. For example, aggrecanase-1 (ADAMTS-4) is inhibited by TIMP-1 (Tortorella et al., 1999). Finally, the most recently discovered TIMP, TIMP-4, has been shown to inhibit mammary tumor growth and may be downregulated in human breast cancers (Wang et al., 1997). Thus it appears that the issue of whether TIMPs defy or exacerbate the effects of cancer-causing agents and mutations is confounded by their multiple and independent functions. Ultimately, the TIMPs may both defy carcinogenicity through their metalloproteinase-inhibitory activity and promote it through their capacity to affect cellular behavior in a metalloproteinase-independent manner.

How MMPs might promote tumor development

Although MMPs are not oncogenic or mutagenic *per se*, there are several routes whereby they can alter signaling and thus affect the process of neoplastic transformation. By degrading extracellular matrices, MMPs alter cell-matrix interactions and cause the release of bioactive ECM fragments (Lukashev and Werb, 1998). MMPs can also cleave a growing list of cell surface molecules, including the tumor suppressor E-cadherin (Sternlicht and Werb, 1999). They can release active growth factors, angiogenic factors and angiogenic inhibitors from the cell surface and ECM (Patterson and Sang, 1997; Suzuki et al., 1997). They can cleave growth factor binding proteins (Fowlkes et al., 1994) and cell surface growth factor receptors (Levi et al., 1996). They can generate an α 1-antitrypsin cleavage product that assists tumor growth and invasion, possibly by modulating NK cell cytotoxicity (Kataoka et al., 1999). They can foster the recruitment of various host cells by altering the stromal environment (Thomasset et al., 1998; Werb, 1997), and they may alter cell cycle checkpoint controls and promote genomic instability by affecting cell adhesion (Tlsty, 1998). MMPs can also induce programmed cell death in anchorage-dependent cells (Alexander et al., 1996; Thomasset et al., 1998), which could either defy tumor progression or exert pressure for the selection of anchorage-independent and apoptosis-resistant subpopulations, and thus promote progression. Therefore, MMPs may contribute in multiple ways to all stages of cancer progression, including initiation.

The evolution of epithelial cancers is also profoundly reliant on the stromal cells that help make up the tumor mass (Rønnov-Jessen et al., 1996). In addition, an altered stromal environment may actually promote neoplastic transformation (Jacobs et al., 1999; Jacoby et al., 1997; Kinzler and Vogelstein, 1998; Willenbacher et al., 1999). Indeed, stromal changes appeared to presage malignant epithelial changes in the WAP-Str1 transgenic mice (Thomasset et al., 1998). Thus, because Str1 can alter the extracellular environment and is itself a stromal product, it may be partly responsible for the tumorigenic effects of an altered stroma.

One of the more appealing prospective mechanisms that might be responsible for the tumor promoting capacity of Str1 is that it may alter E-cadherin/ β -catenin signaling (Figure 7). According to this putative




Figure 7 A hypothetical model of how Str1 may affect cellular behavior via the β -catenin/LEF signal transduction pathway. Following E-cadherin cleavage by Str1 or another metalloproteinase, free cytosolic β -catenin pools are increased. In the absence of Wnt signaling, glycogen synthase kinase 3 β (GSK-3 β) phosphorylates β -catenin, thus targeting it for association with the adenomatous polyposis coli (APC) gene product and axin, ubiquitination, and proteosomal degradation. Alternatively, unphosphorylated β -catenin enters the nucleus where it interacts with LEF/TCF transcription factors, thus regulating the transcription of genes containing functional LEF recognition sites. A number of potential target genes are shown, although only *c-myc*, cyclin-D1 and matrilysin (MMP-7) have been so far shown to respond to β -catenin/LEF transactivation. Molecules indicated in red have been shown to play a causal role in cancer development. Frz, Frizzled family Wnt/Wg receptor; Dsh, Dishevelled family or other GSK inhibitor; Wg, Wingless; ms, mouse

scenario, cleavage of E-cadherin by Str1 or another MMP may increase the cytosolic levels of its intracellular partner, β -catenin. Cytosolic β -catenin, in turn, can be phosphorylated and degraded, or translocated into the nucleus where it then partners with TCF/LEF transcription factors in order to regulate the transcription of genes that contain functional LEF recognition sequences within their promoters (Tlsty, 1998). In support of this mechanism, Str1-induced epithelial-to-mesenchymal conversion is accompanied by E-cadherin cleavage and a rapid redistribution of β -catenin away from cell-cell contacts towards a more cytoplasmic and perinuclear location (Lochter et al., 1997a). Furthermore, Str1 induces an early and sustained upregulation of *cyclin-D1* (ME Lukashev and Z Werb, unpublished results). This is consistent with the above mechanism, because *cyclin-D1* is regulated by β -catenin (Tetsu and McCormick, 1999) and can exert oncogenic effects in the mammary gland (Wang et al., 1994). The *c-myc* proto-oncogene is also regulated by β -catenin/LEF transactivation in colon cancer cells (He et al., 1998), however significant changes in *c-myc* expression were not observed by us during Str1-induced phenotypic conversion in mammary epithelial cells (unpublished results). Finally,

matrilysin (MMP-7) gene expression is also regulated by β -catenin/LEF transactivation (Crawford *et al.*, 1999), and this same pathway may also account for our observation that a number of other MMPs are upregulated during Str1-induced epithelial-to-mesenchymal conversion (Lochter *et al.*, 1997a).

The ability of MMPs to release growth factors from the cell surface and ECM is also likely to play a critical role in cancer development. Some of these growth factors may influence tumor cells directly, while others may influence neighboring cells, such as endothelial cells, that are required to support tumor growth. Indeed, there is a growing awareness that MMPs promote tumor angiogenesis. In a transgenic model of pancreatic islet cell carcinogenesis, broad-range MMP inhibition suppresses the 'angiogenic switch' that occurs during premalignant cancer progression and slows tumor growth during later stages of progression (Bergers *et al.*, 1999). Gelatinase B is probably an important target of such inhibition, in light of its association with premalignant angiogenesis (Coussens *et al.*, 1999) and its critical role in angiogenesis during bone development (Vu *et al.*, 1998). On the other hand, some MMPs, such as metalloelastase (MMP-12), matrilysin and gelatinase B, can cleave plasminogen to generate the angiogenesis inhibitor angiostatin (Patterson and Sang, 1997).

MMPs could also conceivably promote genomic instability by affecting adhesion-dependent cell cycle checkpoint controls (Tlsty, 1998). Interestingly, statistically nonrandom genomic changes were observed by comparative genomic hybridization in both premalignant and malignant mammary gland lesions in WAP-Str1 transgenic mice (Sternlicht *et al.*, 1999). The most prevalent change was a deletion in the mid-distal region of mouse chromosome 4 that was present in 70% of the examined WAP-Str1 mammary lesions. This is consistent with the high incidence of chromo-

some 4 losses seen in two other models of mouse mammary cancer (Donehower *et al.*, 1995; Ritland *et al.*, 1997). In addition, a more recent study indicates that, in one of these models, the highest incidence of loss of heterozygosity occurs in the same mid-distal region of chromosome 4, thus further implicating this region as a putative tumor suppressor locus (Cool and Jolicoeur, 1999). Our own data are also consistent with the possibility that Str1 promotes the accumulation of genetic mutations or the selection and clonal expansion of mutant cells.

MMPs clearly do more than just degrade extracellular matrices, and such matrices are not just passive structures. MMPs can influence cell-matrix, cell-cell and paracrine signals that, in turn, control such basic processes as cellular growth, differentiation, morphogenesis, migration and death. Thus, the importance of MMPs in normal physiologic processes and in pathologic processes other than cancer may also partly stem from their ability to alter cellular signals. Moreover, the role of MMPs in normal physiologic processes and the potential for untoward effects must be considered when designing and undertaking clinical interventions that target the MMPs. A better understanding of the molecular mechanisms responsible for their expanding role in cancer can only benefit the development of more effective therapeutics and therapeutic strategies.

Acknowledgments

We thank R Boudreau, J Xie, DR Williams, and Drs CJ Sympon, A McMillan and RD Cardiff for their assistance. This work was supported by grants from the National Cancer Institute (CA57621 and CA72006), the US Army Medical Research and Materiel Command (DAMD17-97-1-7246), and the US Department of Energy, Office of Health and Environmental Research (DE-AC03-76-SF00098).

References

- Ahmad A, Hanby A, Dublin E, Poulsom R, Smith P, Barnes D, Rubens R, Anglard P and Hart I. (1998). *Am. J. Pathol.*, **152**, 721–728.
- Alexander CM, Howard EW, Bissell MJ and Werb Z. (1996). *J. Cell Biol.*, **135**, 1669–1677.
- Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knauper V, Docherty AJ and Murphy G. (1998). *FEBS Lett.*, **435**, 39–44.
- Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB and Graff JR. (1999). *Cancer Res.*, **59**, 798–802.
- Bergers G, Javaherian K, Lo KM, Folkman J and Hanahan D. (1999). *Science*, **284**, 808–812.
- Bertaux B, Hornebeck W, Eisen AZ and Dubertret L. (1991). *J. Invest. Dermatol.*, **97**, 679–685.
- Birchmeier C, Birchmeier W and Brand-Saberi B. (1996). *Acta Anat. (Basel)*, **156**, 217–226.
- Borsi L, Carnemolla B, Nicolò G, Spina B, Tanara G and Zardi L. (1992). *Int. J. Cancer*, **52**, 688–692.
- Boudreau N, Sympon CJ, Werb Z and Bissell MJ. (1995). *Science*, **267**, 891–893.
- Castagnino P, Soriano JV, Montesano R and Bottaro DP. (1998). *Oncogene*, **17**, 481–492.
- Chesler L, Golde DW, Bersch N and Johnson MD. (1995). *Blood*, **86**, 4506–4515.
- Christofori G and Semb H. (1999). *Trends Biochem. Sci.*, **24**, 73–76.
- Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J and Baselga J. (1999). *Cancer Res.*, **59**, 1196–1201.
- Cool M and Jolicoeur P. (1999). *Cancer Res.*, **59**, 2438–2444.
- Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH and Hanahan D. (1999). *Genes Dev.*, **13**, 1382–1397.
- Coussens LM and Werb Z. (1996). *Chem. Biol.*, **3**, 895–904.
- Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJH, Rubinfeld B, Polakis P and Matrisian LM. (1999). *Oncogene*, **18**, 2883–2891.
- D'Armiento J, DiColandrea T, Dalal SS, Okada Y, Huang MT, Conney AH and Chada K. (1995). *Mol. Cell. Biol.*, **15**, 5732–5739.
- Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR, Murphy G and Reynolds JJ. (1985). *Nature*, **318**, 66–69.
- Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D and Varmus HE. (1995). *Genes Dev.*, **9**, 882–895.
- Fowlkes JL, Engbild JJ, Suzuki K and Nagase H. (1994). *J. Biol. Chem.*, **269**, 25742–25746.
- Gack S, Vallon R, Schaper J, Ruther U and Angel P. (1994). *J. Biol. Chem.*, **269**, 10363–10369.
- Gilles C and Thompson EW. (1996). *Breast J.*, **2**, 83–96.

- Grant GM, Giambernardi TA, Grant AM and Klebe RJ. (1999). *Matrix Biol.*, **18**, 145–148.
- Guede L, Courtemanch L and Stetler-Stevenson M. (1998a). *Blood*, **92**, 1342–1349.
- Guede L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A and Stetler-Stevenson M. (1998b). *J. Clin. Invest.*, **102**, 2002–2010.
- Hayakawa T, Yamashita K, Ohuchi E and Shinagawa A. (1994). *J. Cell Science*, **107**, 2373–2379.
- He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. (1998). *Science*, **281**, 1509–1512.
- Heppner Goss KJ, Brown D and Matrisian LM. (1998). *Int. J. Cancer*, **78**, 629–635.
- Iba K, Albrechtsen R, Gilpin BJ, Loechel F and Wewer UM. (1999). *Am. J. Pathol.*, **154**, 1489–1501.
- Imren S, Kohn DB, Shimada H, Blavier L and DeClerck YA. (1996). *Cancer Res.*, **56**, 2891–2895.
- Jacobs TW, Byrne C, Colditz G, Connolly JL and Schnitt SJ. (1999). *N. Engl. J. Med.*, **340**, 430–436.
- Jacoby RF, Schlack S, Cole CE, Skarbek M, Harris C and Meisner LF. (1997). *Gastroenterology*, **112**, 1398–1403.
- Jung K, Nowak L, Lein M, Priem F, Schnorr D and Loening SA. (1997). *Int. J. Cancer*, **74**, 220–223.
- Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K and Koono M. (1999). *Am. J. Pathol.*, **154**, 457–468.
- Khokha R. (1994). *J. Natl. Cancer Inst.*, **86**, 299–304.
- Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G and Denhardt DT. (1989). *Science*, **243**, 947–950.
- Kinzler KW and Vogelstein B. (1998). *Science*, **280**, 1036–1037.
- Kossakowska AE, Huchcroft SA, Urbanski SJ and Edwards DR. (1996). *Br. J. Cancer*, **73**, 1401–1408.
- Krüger A, Fata JE and Khokha R. (1997). *Blood*, **90**, 1993–2000.
- Leco KJ, Hayden LJ, Sharma RR, Rocheleau H, Greenberg AH and Edwards DR. (1992). *Gene*, **117**, 209–217.
- Levi E, Fridman R, Miao HQ, Ma YS, Yayon A and Vlodavsky I. (1996). *Proc. Natl. Acad. Sci. USA*, **93**, 7069–7074.
- Lindsay CK, Thorgeirsson UP, Tsuda H and Hirohashi S. (1997). *Human Pathol.*, **28**, 359–366.
- Lochter A, Galosy S, Muschler J, Freedman N, Werb Z and Bissell MJ. (1997a). *J. Cell Biol.*, **139**, 1861–1872.
- Lochter A, Srebrow A, Simpson CJ, Terracio N, Werb Z and Bissell MJ. (1997b). *J. Biol. Chem.*, **272**, 5007–5015.
- Logan SK, Garabedian MJ, Campbell CE and Werb Z. (1996). *J. Biol. Chem.*, **271**, 774–782.
- Lu XQ, Levy M, Weinstein IB and Santella RM. (1991). *Cancer Res.*, **51**, 6231–6235.
- Lukashchuk ME and Werb Z. (1998). *Trends Cell Biol.*, **8**, 437–441.
- Lund LR, Rømer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Danø K and Werb Z. (1996). *Development*, **122**, 181–193.
- Martin DC, Rütter U, Sanchez-Sweetman OH, Orr FW and Khokha R. (1996). *Oncogene*, **13**, 569–576.
- Martin DC, Sanchez-Sweetman OH, Ho AT, Inderdeo DS, Tsao MS and Khokha R. (1999). *Lab. Invest.*, **79**, 225–234.
- Martorana AM, Zheng G, Crowe TC, O'Grady RL and Lyons JG. (1998). *Cancer Res.*, **58**, 4970–4979.
- Masson R, Lefebvre O, Noël A, Fahime ME, Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM, Basset P and Rio MC. (1998). *J. Cell Biol.*, **140**, 1535–1541.
- Matrisian LM, Glaichenhaus N, Gesnel MC and Breathnach R. (1985). *EMBO J.*, **4**, 1435–1440.
- McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N and Duffy MJ. (1999). *Int. J. Cancer*, **84**, 44–48.
- Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H and Akiyoshi T. (1997). *Br. J. Cancer*, **76**, 531–536.
- Mitsiades N, Poulaki V, Leone A and Tsokos M. (1999). *Proc. Am. Assoc. Cancer Res.*, **40**, 722.
- Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J and Breathnach R. (1988). *Biochem. J.*, **253**, 187–192.
- Nemeth JA, Rafe A, Steiner M and Goolsby CL. (1996). *Exp. Cell Res.*, **224**, 110–115.
- Oft M, Heider KH and Beug H. (1998). *Current Biol.*, **8**, 1243–1252.
- Ostrowski LE, Finch J, Krieg P, Matrisian L, Patskan G, O'Connell JF, Phillips J, Slaga TJ, Breathnach R and Bowden GT. (1988). *Mol. Carcinog.*, **1**, 13–19.
- Patterson BC and Sang QXA. (1997). *J. Biol. Chem.*, **272**, 28823–28825.
- Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM and Fodstad O. (1997). *Clin. Cancer Res.*, **3**, 1623–1628.
- Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P and Schutz G. (1998). *Cell*, **93**, 531–541.
- Ritland SR, Rowse GJ, Chang Y and Gendler SJ. (1997). *Cancer Res.*, **57**, 3520–3525.
- Ritter LM, Garfield SH and Thorgeirsson UP. (1999). *Biochem. Biophys. Res. Comm.*, **257**, 494–499.
- Rønnov-Jessen L, Petersen OW and Bissell MJ. (1996). *Physiol. Rev.*, **76**, 69–125.
- Rudolph-Owen LA, Chan R, Muller WJ and Matrisian LM. (1998). *Cancer Res.*, **58**, 5500–5506.
- Sanchez-Lopez R, Nicholson R, Gesnel MC, Matrisian LM and Breathnach R. (1988). *J. Biol. Chem.*, **263**, 11892–11899.
- Shoji A, Sakamoto Y, Tsuchiya T, Moriyama K, Kaneko T, Okubo T, Umeda M and Miyazaki K. (1997). *Carcinogenesis*, **18**, 2093–2100.
- Soloway PD, Alexander CM, Werb Z and Jaenisch R. (1996). *Oncogene*, **13**, 2307–2314.
- Staskus PW, Masiarz FR, Pallanck LJ and Hawkes SP. (1991). *J. Biol. Chem.*, **266**, 449–454.
- Sternlicht MD, Lochter A, Simpson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ and Werb Z. (1999). *Cell*, **98**, 137–146.
- Sternlicht MD and Werb Z. (1999). *Guidebook to the Extracellular Matrix and Adhesion Proteins*. Kreis T and Vale R. (eds). Oxford University Press: Oxford, pp. 503–562.
- Stetler-Stevenson WG, Bersch N and Golde DW. (1992). *FEBS Lett.*, **296**, 231–234.
- Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT and Liotta LA. (1990). *J. Biol. Chem.*, **265**, 13933–13938.
- Suzuki M, Raab G, Moses MA, Fernandez CA and Klagsburn M. (1997). *J. Biol. Chem.*, **272**, 31730–31737.
- Simpson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissell MJ and Werb Z. (1994). *J. Cell Biol.*, **125**, 681–693 [erratum in *J. Cell Biol.*, **132**, 752].
- Tetsu O and McCormick F. (1999). *Nature*, **398**, 422–426.
- Thomasset N, Lochter A, Simpson CJ, Lund LR, Williams DR, Behrendtsen O, Werb Z and Bissell MJ. (1998). *Am. J. Pathol.*, **153**, 457–467.
- Tlsty TD. (1998). *Curr. Opin. Cell Biol.*, **10**, 647–653.
- Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC, Hollis GF, Newton RC, Magolda RL, Trzaskos JM and Arner EC. (1999). *Science*, **284**, 1664–1666.
- Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP and Vande Woude GF. (1994). *Science*, **263**, 98–101.

- Uría JA, Ferrando AA, Velasco G, Freije JM and López-Otín C. (1994). *Cancer Res.*, **54**, 2091–2094.
- Vallorosi CJ, Day KC, Zhao X and Day ML. (1999). *Proc. Am. Assoc. Cancer Res.*, **40**, 721.
- Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M and Iruela-Arispa ML. (1999). *J. Biol. Chem.*, **274**, 23349–23357.
- Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM and Werb Z. (1998). *Cell*, **93**, 411–422.
- Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM and Shi YE. (1997). *Oncogene*, **14**, 2767–2774.
- Wang TC, Cardiff RD, Zuckerberg L, Lees E, Arnold A and Schmidt EV. (1994). *Nature*, **369**, 669–671.
- Werb Z. (1997). *Cell*, **91**, 439–442.
- Werb Z and Yan Y. (1998). *Science*, **282**, 1279–1280.
- Willenbacher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH and Waldman FM. (1999). *Am. J. Pathol.*, **154**, 1825–1830.
- Wilson CL, Heppner KJ, Labosky PA, Hogan BL and Matrisian LM. (1997). *Proc. Natl. Acad. Sci. (USA)*, **94**, 1402–1407.
- Witty JP, Wright JH and Matrisian LM. (1995). *Mol. Biol. Cell*, **6**, 1287–1303.
- Wright JH, McDonnell S, Portella G, Bowden GT, Balmain A and Matrisian LM. (1994). *Mol. Carcinog.*, **10**, 207–215.
- Yoshiji H, Gomez DE and Thorgeirsson UP. (1996). *Int. J. Cancer*, **69**, 131–134.
- Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M, Sinha CC and Thorgeirsson UP. (1998). *Int. J. Cancer*, **75**, 81–87.
- Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W and Guillem JG. (1995). *Clin. Cancer Res.*, **1**, 899–906.